ONC-783 for Cancer

Not yet recruiting at 1 trial location
PZ
YW
Overseen ByYao Wang, MD, MS
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.

Are You a Good Fit for This Trial?

This trial is for adults over 18 with advanced or metastatic pancreatic, ovarian, colorectal, or breast cancer. Participants must be in relatively good health (ECOG score ≤ 1), weigh at least 40 kg, and have a life expectancy of more than 12 weeks. They should have measurable tumors and proper organ function. Women must not be pregnant and agree to use effective contraception.

Inclusion Criteria

I have a tumor that can be measured by standard criteria.
I am 18 years old or older.
I am either male or female.
See 6 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation Treatment

Participants receive ONC-783 via SC injection in a dose-escalation study to evaluate safety, PK, and efficacy

24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • ONC-783

Trial Overview

The study tests ONC-783's safety, how the body processes it (pharmacokinetics), and its effectiveness against certain solid tumors. It's an early-stage trial (Phase I) where doses increase gradually to find the safest dose that might work.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: ONC-783Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

OncoC4, Inc.

Lead Sponsor

Trials
8
Recruited
1,800+